Keynote & Plenary Speakers

Get a sneak peek below at the exciting keynote lectures and plenary sessions that will be part of the IPVC 2024 scientific program.

All times below are in Edinburgh, UK Local Time — Greenwich Mean Time (GMT).

If you want to be the first to know all IPVC 2024 updates, sign up for our newsletter here.

Tuesday, November 12

OPENING KEYNOTE AND INTRODUCTION TO IPVC

 The role of respectful partnership in the delivery of global health goals, with particular reference to Scotland and Malawi.

Heather Cubie

Wednesday, November 13

PLENARY SESSION 1: HPV- The Fundamentals

- HPV replication throughout the life cycle
 Alison McBride (USA)
- HPV from infection to cancer
 Karl Munger (USA)
- HPV signal transduction-a target for anti-virals Michelle Ozbun (USA)

PLENARY SESSION 2: Therapeutic cancer vaccines

- General concepts of cancer interception vaccines
 Olivera Finn
- Combination immunotherapy of HPV-induced cancers, including T cell induction by therapeutic vaccines
 Cornelis Melief
- Clinical trials and promising results to date of therapeutic vaccines (together with immunotherapeutic agents) for HPV-related head and neck and cervical cancers

Katharine Price

Thursday, November 14

PLENARY SESSION 3: Rapid, low-cost HPV cervical screening technologies to meet elimination.

- Overview of current and emerging technologies for lowcost tests to meet elimination goals introducing the concept of WHO prequalification of assays
 Maribel Almonte
- Screening trials with treatment algorithms of care as one aspect of the elimination program in LMIC
 Rakiya Saidu
- Reaching the third target: Treatment for all.
 Hennie Botha

Friday, November 15

PLENARY SESSION 4: Implementation Science

 An overview of principles of implementation science research with an HPV lens

Maria Fernandez

 Implementation science of cervical cancer prevention strategies in Nigeria

Juliet Iwelunmor

 Use of implementation science to strengthen cervical cancer prevention in Argentina

Silvina Arrossi

CLOSING PLENARY

- Vaccine Technology (preventative and therapeutic)
 Ian Frazer
- •Will Australia be the first to eliminate cervical cancer?

Suzanne Garland (Australia)

	16:30-18:00
	OPENING CEREMONY AND KEYNOTE
Tuesday,	LECTURE
April 18	 Comparing and Contrasting COVID-19 Control
	with HPV Control and Elimination
	Barney Graham, USA

	11:00-12:30
	PLENARY SESSION 1
	• One-dose HPV vaccination overview and a focus
	on the KENSHE data
Wednesday,	Ruanne Barnabas, USA
April 19	 New prophylactic HPV vaccines
	Richard Roden, USA
	 Therapeutic vaccines in particular with
	clinical outcomes such as CIN 3
	Mayumi Nakagawa, USA
	8:30-10:00
	PLENARY SESSION 2
	 Lessons learned from other disease control
	programs such as HIV
	Helen Rees, South Africa
	• What can we learn from the hepatitis B model
	in elimination of HPV-related diseases?
	Mark Kane, USA
	 Anal cancer control approaches
	Joel Palefsky, USA
Thursday,	
April 20	16:40-18:10
	PLENARY SESSION 3
	Mastomys Coucha: a unique animal model for
	papillomavirus-induced skin carcinogenesis
	Frank Rosl, Germany
	• Pros and cons of Beta HPVs as causative agents
	in skin cancer
	Denise Galloway, USA *Special Tribute to Massimo Tommasino en his
	*Special Tribute to Massimo Tommasino on his
	work on Epidemiology and Biology of Beta Human

Papillomavirus Types

11:45-13:15

PLENARY SESSION 4

• Covid-19 effect on cervical screening

Mona Saraiya, USA

 Re-invigorating efforts towards cervical cancer elimination: mitigating the impact of Covid-19

Karen Canfell, Australia

Friday, April 21 What will it take (and how to) achieve cervical cancer elimination goal by 2030 with a perspective for low and middle income countries?

Yin Ling Woo, Malaysia

16:00-17:15

CLOSING CEREMONY AND KEYNOTE LECTURE

 The future is now Douglas Lowy, USA

Tuesday, November 16, 2021

15:30-17:15

Successful vaccines — what's the secret?

*Prof. Mark K. Slifka, USA*Wednesday, November 17, 2021 14:30-16:00

Public trust in vaccines

Dr. Maya J. Goldenberg, Canada

Immunotherapy for HPV

Dr. Sjoerd van der Burg, Netherlands

Next-generation HPV vaccines integrating biology and engineering

Dr. Robert L. Garcea, USAThursday, November 18, 2021 10:00-11:30

Inequity in global access to health and justice

Dr. Gina Ogilvie. Canada

Global HPV vaccine supply & demand and the impact of the COVID-19 pandemic

Dr. Tania Cernuschi, Switzerland

Cervical cancer prevention and management as part of comprehensive sexual and reproductive health care for women in sub-Saharan Africa

Dr. Peter Jay Hotez, USAThursday, November 18, 2021 14:30-15:30

HNSCC development and progression: Avenues for therapeutic development

Dr. Jennifer R. Grandis, USA

RRP: the paradigm for HPV immune evasion

Dr. Vincent R. Bonagura, USAFriday, November 19, 2021 10:30-11:30

Exploiting DNA damage repair by HPV

Prof. Laimonis A Laimins, USA

Vaginal and anal microbiome

Prof. Adam Burgener, USAFriday, November 19, 2021
15:30-17:00

Research in HPV: past, present, and future

Dr. Eduardo Franco, CanadaScientific Program